Your browser doesn't support javascript.
loading
Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.
Gastaldelli, Amalia; Repetto, Enrico; Guja, Cristian; Hardy, Elise; Han, Jenny; Jabbour, Serge A; Ferrannini, Ele.
Afiliação
  • Gastaldelli A; CNR Institute of Clinical Physiology, Pisa, Italy.
  • Repetto E; Global Medical CVRM, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, United States.
  • Guja C; Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
  • Hardy E; Late CVRM, BioPharmaceuticals R&D, Gaithersburg, Maryland, United States.
  • Han J; Pharmapace Inc., San Diego, California, United States.
  • Jabbour SA; Division of Endocrinology, Diabetes and Metabolic Diseases, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, United States.
  • Ferrannini E; CNR Institute of Clinical Physiology, Pisa, Italy.
Diabetes Obes Metab ; 22(3): 393-403, 2020 03.
Article em En | MEDLINE | ID: mdl-31692226
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article